105 results about "Encephalopathy" patented technology

A chimeric autoantibody receptor (CAAR) that enables targeting of an immune cell to autoantibody producing B cells. The CAAR includes an autoantigen or fragment thereof that is bound by autoantibodies associated with neurological autoimmune disease primarily targeting the central nervous system. Also disclosed is a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid sequence encoding an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system, a transmembrane domain, and an intracellular signaling domain, a vector comprising a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), a genetically modified immune cell comprising the nucleic acid molecule encoding the CAAR and use of the immune cell in the treatment or prevention of a neurological autoimmune disease primarily targeting the central nervous system, such as an autoimmune encephalopathy or encephalomyelopathy, preferably anti-NMDAR encephalitis.

The invention discloses a pharmaceutical composition for treating KCNQ2 developmental epileptic encephalopathy, a nucleic acid construct and application of the pharmaceutical composition and the nucleic acid construct. According to the invention, by introducing a nucleic acid construct carrying the hKCNQ2 gene into a KCNQ2A294V / + developmental epileptic encephalopathy animal model and a human forebrain neuron model, the effectiveness of the nucleic acid construct in improving the expression level of the KCNQ2 and improving related neuropathological mechanisms is verified. Not only is a new hope provided for treatment of KCNQ2-related developmental epileptic encephalopathy provided, but also a new direction is opened up for application of gene therapy in neurodevelopmental diseases.

This invention discloses a polyethylene glycol-modified magnesium boride nanosheet and its application in treating acute liver failure and hepatic encephalopathy caused by acetaminophen. The nanosheet uses magnesium boride nanosheets as a core, with polyethylene glycol modified on the surface to improve biocompatibility. The nanosheet of this invention exhibits good antioxidant properties and can be used to prepare nanomedicines for treating acute liver failure and / or hepatic encephalopathy caused by acetaminophen. It generates reducing hydrogen gas through a hydrolysis reaction, effectively scavenging reactive oxygen species at the site of liver failure, thereby inhibiting inflammatory responses and effectively alleviating symptoms caused by acute liver failure.

The application discloses application of a Fructus Mume pill in preparation of a medicine for treating diabetic encephalopathy, and finds that there is a clear correlation between the Fructus Mume pill and the diabetic encephalopathy. Research results show that the Fructus Mume pill can improve the abnormal metabolic state of a diabetic model mouse, reduce learning and memory dysfunction and cognitive impairment under a diabetic state, and has a good prevention and treatment effect on the diabetic encephalopathy. The application clearly defines the pharmacological effect of the Fructus Mume pill in preventing and treating the diabetic encephalopathy and a possible action mechanism, and provides an experimental basis for TCM intervention on the diabetic encephalopathy. The application provides a new train of thought for research and development of a medicine related to the diabetic encephalopathy, and has a good application prospect.

The invention belongs to the technical field of medicines, and particularly relates to application of penicillin tenuipes in preparation of a product for preventing or treating ischemic encephalopathy, cell experiments and animal experiments show that penicillin tenuipes has a good treatment effect on cerebral thrombosis and middle artery embolism, can obviously improve behavioral scores after ischemia, and can be used for preparing a medicine for preventing or treating ischemic encephalopathy. And cerebral thrombus and blood vessel diameter conditions. The penicillin tenuipes also has an anti-inflammatory effect. Therefore, the compound can be used for preparing medicines for preventing or treating ischemic encephalopathy.

The application discloses a kind of based on brain structure image's hepatic encephalopathy evaluation method and system, the method includes: obtaining the brain structure image data of subject brain;Based on brain structure image data, the feature parameter of characterizing brain tissue morphology is extracted;The characteristic parameter is handled by pre-training disease progression evaluation model, and the space-time progression trajectory of brain structure abnormality is inferred;Based on space-time progression trajectory, the disease subtype and disease progression stage to which the subject belongs are determined;Based on disease subtype and disease progression stage, evaluation information for characterizing the disease state of hepatic encephalopathy is generated.The space-time progression trajectory of brain structure abnormality is inferred based on cross-sectional image data, which overcomes the dependence on massive longitudinal tracking data, realizes the objective typing and staging of hepatic encephalopathy based on neurobiology, thereby effectively solving the technical problems of difficult to track disease evolution and individualized evaluation.

A TIPS (Transient Invasive Stent) for flow restriction includes a bare stent with a fixed stent connected to one side. A flow-restricting stent is disposed inside the fixed stent. The flow-restricting stent has a conical structure, with the larger end of the conical stent connected to the inner side of the fixed stent, and the smaller end of the conical stent facing the other end of the fixed stent. A drug-eluting layer is disposed inside the fixed stent. In this application, the flow-restricting stent is a streamlined cone shape with a diameter that gradually decreases from one end to the other. This conical design reduces blood flow turbulence and recirculation, lowers the risk of thrombosis, maintains high stent patency, and more rationally balances the relationship between portal hypertension and hepatic encephalopathy, thus improving patients' quality of life. In some patients, it can more stably maintain the postoperative portal vein pressure gradient within the safe range of 10-12 mmHg. The conical structure achieves a smooth pressure gradient change through a gradually decreasing diameter, which is more in line with the principles of fluid dynamics and has high clinical value in preventing hepatic encephalopathy.

The invention provides an image-clinical characterization-combined multi-endpoint prognosis evaluation method for transjugular vein intrahepatic portal vein shunt, which comprises the following steps of: constructing a few-label portal vein segmentation module to obtain a preoperative CT portal vein label of a full-dose patient, and extracting deep learning features and radiomics features of the region; establishing a multi-modal interactive representation learning module for implementation, and performing cross-modal fusion with clinical features to form unified representation; and designing a multi-endpoint prognosis prediction module, inputting the data to a plurality of prognosis task decoders for postoperative survival, portal vein pressure gradient, hepatic encephalopathy prediction and the like, and adopting a multi-task learning optimization model to obtain a postoperative multi-endpoint prognosis evaluation result. According to the method, efficient fusion and multi-endpoint prognosis prediction of images and clinical information can be realized under limited labeling, clinical doctors can be assisted in preoperative patient screening and treatment scheme making, and the method has good clinical application value.

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein Ring A, Ring B, R1, R2, R3, R12, and L are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calcium ion channel Cav 2.3. Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases modulated Cav 2.3, including epilepsy, neurodegenerative conditions such as Parkinson's disease, focal, drug-resistant forms of epilepsy, and other neurological disorders such as developmental and epileptic encephalopathies and Phelan-McDermid and Fragile X syndromes.

The present application relates to the technical field of medical apparatus and instruments, and discloses a neonatal hypothermia portable treatment device and a body temperature regulation system, aiming to solve the problem that the prior art cannot adapt to the transfer scene and is prone to body temperature out of control when a neonatal hypoxic-ischemic encephalopathy is transferred, the body temperature regulation system comprises four modules of information acquisition, temperature control decision, temperature control execution and information connection, the information acquisition module collects and discriminates body temperature, physiological parameters and transfer interference data; the temperature control decision module generates temperature control instructions and interference compensation strategies in combination with preset parameters of body weight and according to scenes; the temperature control execution module drives components to land on the ground according to instructions and feeds back the state; and the information connection module summarizes data and synchronously transfers the data into a hospital admission system, so that the transition body temperature is stably controlled during the transfer, the hospital admission first-aid operation is smoothly connected, and the technical blank of pre-treatment body temperature transition management during short-distance transfer is filled.

The disclosure relates to polynucleotides, e.g., viral genomes, encoding syntaxin-binding protein-1 (STXBP1), vectors, e.g., adeno-associated virus (AAV) particles, comprising said polynucleotides, compositions comprising said polynucleotides or vectors, and methods of making or delivering to a cell or subject. The polynucleotides, vectors, compositions, and methods of the present disclosure are useful for the treatment of subjects who have, have been diagnosed with having, or are at risk of having a STXBP1-related disorder, e.g., STXBP1 Developmental and Epileptic Encephalopathy (DEE) and / or other STXBP1-related disorders, or at least one symptom thereof.

The application relates to the biomedical application field of inorganic materials, and particularly relates to application of lanthanum carbonate in preparation of a medicine for treating hepatic encephalopathy. The application relates to application of lanthanum carbonate in preparation of a medicine for treating hepatic encephalopathy, wherein the medicine comprises lanthanum carbonate and pharmaceutically acceptable adjuvants, and the lanthanum carbonate comprises any one or more of lanthanum carbonate hydrate and basic lanthanum carbonate. The application is based on the fact that glutamine enzyme can reduce blood ammonia, and the hepatic encephalopathy is reversed by reducing blood ammonia and systemic inflammation, the liver function is recovered by regulating inflammation, thereby helping to cure the hepatic encephalopathy, and good treatment effect is shown, so that a new candidate medicine for clinically treating the hepatic encephalopathy is provided.

The invention discloses a method, equipment, medium and program product for evaluating the treatment effect of levosimendan on sepsis-related encephalopathy. According to the method, the treatment effect of the levosimendan on the sepsis-related encephalopathy is evaluated on the basis of cerebral blood flow data, clearance rate data of a colloidal lymphatic system and / or expression data of AQP4, and the treatment effect of the levosimendan on the sepsis-related encephalopathy can be effectively evaluated. Therefore, further guidance is provided for optimizing the treatment condition and research of the sepsis-related encephalopathy by the levosimendan, and a clinician can be guided to formulate an individualized treatment scheme for a patient.

The invention relates to application of sevelamer. The medicine is particularly applied to treatment of hepatic encephalopathy. According to the method for orally taking the sevelamer compound preparation, the level of ammonia in blood can be remarkably reduced to the normal level, bile acid in the intestinal tract is combined, system inflammation is reduced, and therefore the sevelamer compound preparation is beneficial to curing hepatic encephalopathy, and no obvious side effect is found; the sevelamer oral administration method provided by the invention has a remarkable treatment effect on hepatic encephalopathy, a new candidate treatment medicine is expected to be brought to clinical hepatic encephalopathy, and meanwhile, the range of indications of sevelamer in clinical treatment is widened.

Provided herein are methods, compounds, and compositions for reducing expression of SCN2A in a subject. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate an SCN1A related disease or disorder (e.g., Dravet syndrome) in a subject in need.

The invention discloses a method and a system for predicting cerebrospinal fluid of an HIV (Human Immunodeficiency Virus) combined brain junction patient based on machine learning, and the method comprises the steps: obtaining the information and prognosis evaluation result of the cerebrospinal fluid of the HIV combined brain junction patient through a data center of a medical institution, and constructing an initial data feature set; performing de-noising processing on the preprocessed data set through a DBscan clustering strategy to obtain an important feature data set; dividing the important feature data set into a training set and a test set, and training and testing each machine learning algorithm model; screening out the model with the optimal performance as an optimized machine learning algorithm model; performing screening and analysis by optimizing a machine learning algorithm model to obtain an association rule among the key features; predicting cerebrospinal fluid information to be predicted through the model to obtain a predicted prognosis result; constructing a mapping model based on the association rule; and outputting a targeted clinical guidance strategy through the mapping model.

Provided herein are compounds and pharmaceutical compositions comprising a therapeutically effective amount of such compounds, or pharmaceutically acceptable salts, and a pharmaceutically acceptable excipient, and methods of treating neurodevelopmental diseases or disorders (NDD) and developmental and epileptic encephalopathy (DEE), comprising administering such compounds, or pharmaceutically acceptable salts, and pharmaceutical compositions, to pediatric patients.

The disclosure relates to adeno-associated (AAV) particles comprising viral genomes encoding cyclin-dependent kinase-like 5 (CDKL5) proteins and peptides, compositions comprising said AAV particles, and methods for making and delivering said AAV particles to a cell or subject. The AAV particles, compositions, and methods of the present disclosure are useful for the treatment of subjects who have, have been diagnosed with having, or are at risk of having a CDKL5 deficiency disorder (CDD), developmental and epileptic encephalopathy 2, atypical Rett syndrome, and / or other CDKL5-related disorders or at least one symptom thereof.

This invention discloses a multimodal health management method and system for TIPS postoperative care, specifically relating to the field of medical and health management technology. It involves constructing a postoperative multimodal follow-up dataset by collecting patient health consultation records, dietary protein intake records, oral medication adherence records, and doctor-patient feedback records. Through consultation topic classification, protein intake deviation identification, medication adherence breakpoint detection, and feedback tendency determination, a set of behavioral events is extracted. Within the same follow-up period, co-occurrence associations of consultation, diet, medication, and feedback events are established to generate a risk trigger chain for hepatic encephalopathy. Based on the risk trigger chain, the intervention type is determined, generating individualized intervention instructions such as dietary guidance, medication reminders, and health consultation responses. These intervention instructions are then pushed to both the patient and healthcare professionals, collecting execution and treatment feedback and writing it back into the dataset to form a closed-loop follow-up update. Finally, the updated data is used to correct the risk trigger chain and automatically generate intervention instructions for the next cycle.

Diagnostic and therapeutic methods for neurodegenerative diseases. Are provided involving assaying abnormal proteins (hyperphosphorylated tau, α-synuclein, TDP-43) associated with neuronal turnover inhibition or promotion in patient samples. Abnormal protein expression and apoptotic activity are detected, aiding disease progression assessment. Therapeutically, a method is provided for treating neurodegenerative diseases, administering compounds promoting neuronal turnover or modulating proteins involved in the process. The invention extends to identifying suitable drugs, employing neuronal turnover induction, miRNA modulation, and protein activity inhibition or enhancement. The claims also encompass various species, tissues, and cultured cells. Furthermore, the invention is applicable to diverse neurodegenerative diseases with abnormal protein accumulation, presenting novel diagnostic and treatment approaches.

The invention is directed to immunological compositions of one or more peptides containing epitopes of PGN, LTA and LPS molecules that induce an immunological response in a mammal, and to multiple antibodies that bind to these epitopes. Immunological compositions and antibodies disclosed herein can be used in the treatment and / or prevention of human health disorders such as bacterial sepsis, inflammation, cancers, tumors, inflammatory diseases and disorders, and neurodegenerative disorders such as, but not limited to Alzheimer's disease, frontotemporal dementia, chronic traumatic encephalopathy (CTE), Lewy body dementia and / or limbic predominant age-related TDP-43 encephalopathy (LATE).

This invention provides methods of detecting biomarkers in the biofluid of sepsis-associated encephalopathy (SAE) patients, including but not limited to glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase LI, Tan protein, Neurofilament light chain (NF-L), myelin basic protein (MBP), secretogranin, Copeptin, total all-spectrin, all-spectrin breakdown products (SBDP, including SBDP145, SBDP150, SBDP120 all-spectrin N-terminal fragment or SBDP150N), neuron specific enolase (NSE), mature brain derived neurotrophic factor (BDNF), and full-length Pro-BDNF. These biomarker peptides are markers of axonal and blood brain barrier integrity which can be used to diagnose SAE and to assess and predict cognitive performance and outcomes in acute presentations of sepsis.

The present technology relates to methods of treating behavioral problems and seizures in a subject having developmental and epileptic encephalopathy (DEE) by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein behavioral problems are treated in the subject.

Provided herein are methods and compositions for treating neurological diseases (e.g., neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease, dementia, a tauopathy, chronic traumatic encephalopathy (CTE), traumatic brain injury (TBI), mild cognitive impairment); psychiatric disorders (e.g., bipolar disorder, schizophrenia, depression, anxiety, post-traumatic stress disorder, obsessive compulsive disorder); inflammation in the central nervous system) using lithium salts, activators that increase the expression or activity of the RE1 silencing transcription factor (REST), or a combination thereof, or in combination with an additional agent.

The application relates to a senile encephalopathy risk prediction method and system based on an attention mechanism and feature weighting optimization, which comprises the following steps: S1, multi-source heterogeneous data acquisition and preprocessing; S2, calculating the attention weight of each feature on risk prediction based on a multi-head self-attention mechanism, and constructing a dynamic feature weighting representation; S3, introducing a Mish activation function to perform nonlinear transformation on the weighted features, and enhancing the fitting capability of the model to complex nonlinear relationships; S4, constructing a feature selection mechanism based on the attention weight, and adaptively screening a key feature subset; S5, based on the key feature subset, adopting a Transformer encoder to construct a senile encephalopathy risk prediction model, and outputting the probability and risk grade of each risk category. The application can realize more accurate, efficient and adaptive senile encephalopathy risk prediction.

5′-O-Phenylacetyluridine effectively delivers both phenylacetate and uridine to a subject. It can be used to treat hepatic encephalopathy and genetic disorders of the hepatic nitrogen cycle.

To provide methods, compounds and compositions for reducing the expression of SCN2A in subjects.SOLUTION: Such methods, compounds and compositions are useful for treating, preventing, delaying or ameliorating a SCN1A associated disease or disorder (e.g., Dravet syndrome) in a subject in need thereof. The disclosure provides compositions, compounds and methods for modulating expression of sodium voltage-gated channel alpha subunit 2 (SCN2A) in order to treat sodium voltage-gated channel alpha subunit 1 (SCN1A)-associated diseases such as SCN1A encephalopathies, including Dravet syndrome (severe myoclonic epilepsy of infancy (SMEI)), epilepsy, generalized epilepsy with febrile seizures, familial febrile seizures, migraines, and early infantile epileptic encephalopathy 6.SELECTED DRAWING: None

The invention discloses a method for constructing a diabetic encephalopathy mouse model through combined induction of cadmium and fructose. According to the method, the diabetes contamination dosage is promoted by adjusting cadmium; the condition that the fasting blood glucose of the mouse is greater than or equal to 11.1 mmol / L, urine glucose inspection is positive, and mine field experiments, new object recognition experiments and water maze mouse learning and memory experiments verify that the cognitive dysfunction of the mouse successfully induces the diabetic encephalopathy. According to the method, through combined induction of the fructose solution and cadmium, the modeling condition is met, and the cost is reduced. The model manufacturing process has little harm to animal bodies and conforms to the international and domestic animal welfare principle.